Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.76 |
| ▸ | BRD4 | O60885 | 4/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640549 | 0.90 | EGLN3 (0.78) | EGLN3BRD4EGLN1MAPK1 | |
| SCHEMBL12727659 | 0.86 | EGLN3 (0.70) | EGLN3BRD4EGLN1 | |
| SCHEMBL1640593 | 0.86 | EGLN3 (0.83) | EGLN3BRD4EGLN1 | |
| SCHEMBL1640295 | 0.86 | EGLN3 (1.00) | EGLN3BRD4EGLN1ALDH1A1 | |
| SCHEMBL1642122 | 0.85 | EGLN3 (0.75) | EGLN3BRD4EGLN1ALDH1A1HIF1A | |
| SCHEMBL1642745 | 0.84 | EGLN3 (0.83) | EGLN3EGLN1MAPK1HIF1A | |
| SCHEMBL1642321 | 0.83 | EGLN3 (0.78) | EGLN3BRD4EGLN1ALDH1A1HIF1A | |
| SCHEMBL13568141 | 0.83 | EGLN3 (0.78) | EGLN3BRD4EGLN1 | |
| SCHEMBL1642598 | 0.82 | EGLN3 (0.90) | EGLN3EGLN1ALDH1A1 | |
| SCHEMBL1642011 | 0.81 | EGLN3 (0.88) | EGLN3EGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885BRD4 3195/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.